Product Information
CITALOPRAM HBR 10 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.0300 per EA under NDC 69097082212. Its NADAC has been published 522 times since Nov 23, 2016.
FDA first approved this application on Oct 3, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/1
Manufacturer
Cipla USA Inc.NDC
69097082212
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
11/18/2026
Active Ingredients
CITALOPRAM HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077534FDA Approved
10/3/2006
TE Code
AB
On Market Since
7/22/2016
Pharmacological Classes
Price Statistics
The NADAC for CITALOPRAM HBR 10 MG TABLET has been published 522 times since Nov 23, 2016, and over the history we have for it it has declined 6.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0300 per EA |
|---|---|
| All-time high | $0.0359 (Jan 11, 2017) |
| All-time low | $0.0204 (May 22, 2024) |
| 52-week high | $0.0300 |
| 52-week low | $0.0241 |
| Median price | $0.0271 |
| Average price | $0.0274 |
| Largest weekly change | +24.2% (Jun 19, 2024) |
| Weeks tracked | 522 |
| Tracking since | Nov 23, 2016 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 13% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Citalopram market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CITALOPRAM HBR 10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CITALOPRAM HBR 10 MG TABLET, manufactured by Cipla USA Inc., is $0.0300 per EA (NDC 69097082212), effective Nov 18, 2026.
How has the price of CITALOPRAM HBR 10 MG TABLET changed over time?
Over the history we have for it, the NADAC for CITALOPRAM HBR 10 MG TABLET has declined 6.8%. It has been tracked across 522 weekly CMS publications since Nov 23, 2016.
What are the highest and lowest recorded NADAC prices for CITALOPRAM HBR 10 MG TABLET?
Since Nov 23, 2016, the NADAC for CITALOPRAM HBR 10 MG TABLET has ranged from a low of $0.0204 (May 22, 2024) to a high of $0.0359 (Jan 11, 2017), with a median of $0.0271 per EA.
Are there cheaper alternatives to CITALOPRAM HBR 10 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CITALOPRAM HBR 10 MG TABLET, is $0.0261 per EA — about 13% below CITALOPRAM HBR 10 MG TABLET.
Who manufactures CITALOPRAM HBR 10 MG TABLET?
CITALOPRAM HBR 10 MG TABLET (NDC 69097082212) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.